Financing and reimbursement of approved advanced therapies in several European countries.

Carolina Iglesias Lopez, M. Antonieta Agusti Escasany, Antonio Vallano*, Mercè Obach

*Autor correspondiente de este trabajo

Producción científica: Contribución a una revistaArtículoInvestigaciónrevisión exhaustiva

5 Citas (Scopus)

Resumen

Objectives: The uncertainty in the cost-benefit of advanced therapy medicinal products (ATMPs) is a current challenge for their reimbursement in health systems. This study aimed to provide a comparative analysis of the National Health Authorities (NHAs) reimbursement recommendations issued in different European countries.

Methods: The NHA reimbursement recommendations for the approved ATMPs were compared among 8 European Union (EU) Countries (EU8: Ireland, England/Wales, Scotland, The Netherlands, France, Germany, Spain, and Italy). The search was carried out until December 31, 2021.

Results: A total of 19 approved ATMPs and 76 appraisal reports were analyzed. The majority of the ATMPs were reimbursed, although with uncertainty in added therapeutic value. No relationship between the type of the European Medicines Agency approval and reimbursement was found. Managed entry agreements, such as payment by results, were necessary to ensure market access. The main issue during the evaluation was to base the cost-effectiveness analyses on assumptions because of the limited long-term data. The estimated incremental cost-effectiveness ratio among countries reveals high variability. Overall, the median time to NHA recommendation for the EU8 is in the range of 9 to 17 months.

Conclusions: Transparent, harmonized, and systematic assessments across the EU NHAs in terms of cost-effectiveness, added therapeutic value, and grade of innovativeness are needed. This could lead to a more aligned access, increasing the EU market attractiveness and raising public fairness in terms of patient access and pricing.
Idioma originalInglés
Número de artículo36646280
Páginas (desde-hasta)841-853
Número de páginas13
PublicaciónValue in health
Volumen26
N.º6
DOI
EstadoPublicada - jun 2023

Palabras clave

  • Added therapeutic value
  • Advanced medicinal products
  • Financing government
  • Health technology assessment
  • Market access

Huella

Profundice en los temas de investigación de 'Financing and reimbursement of approved advanced therapies in several European countries.'. En conjunto forman una huella única.

Citar esto